Literature DB >> 1682065

In vivo demonstration of cardiac beta 2-adrenoreceptor sensitization by beta 1-antagonist treatment.

J A Hall1, M C Petch, M J Brown.   

Abstract

Treatment with beta 1-selective antagonists causes selective sensitization of isolated strips of human atrial myocardium to the inotropic action of epinephrine and beta 2-agonists but not of norepinephrine. To determine whether beta 1-selective antagonist treatment alters the responsiveness of cardiac beta 2-adrenoreceptors in vivo, we measured the positive chronotropic responses to salbutamol injected into the right coronary artery. Ten patients treated with atenolol (50-100 mg daily) were compared with 10 patients not treated with beta-blockers. The mean dose required to cause an increase in heart rate of 30 beats/min was 2.29 micrograms (log dose 0.36 +/- 0.12 micrograms [mean +/- SEM]) in the atenolol-treated patients. In the non-beta-blocker-treated patients, the dose required to cause an increase in heart rate of 30 beats/min was significantly greater, 8.91 micrograms (log dose 0.95 +/- 0.11 micrograms) (p less than 0.005). We conclude that treatment with beta 1-selective beta-blockers leads to increased cardiac responsiveness to beta 2-adrenoreceptor stimulation. This may be the underlying mechanism of the beta-blocker withdrawal syndrome and may make the heart more susceptible to the adverse effects of epinephrine in situations of stress (e.g., myocardial infarction).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1682065     DOI: 10.1161/01.res.69.4.959

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  12 in total

Review 1.  Alterations in adrenergic receptor signaling in heart failure.

Authors:  S Lamba; W T Abraham
Journal:  Heart Fail Rev       Date:  2000-03       Impact factor: 4.214

2.  To beta block or better block?

Authors:  M J Brown
Journal:  BMJ       Date:  1995-09-16

Review 3.  Beta-adrenoceptor blocker treatment and the cardiac beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure.

Authors:  Otto-Erich Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-11       Impact factor: 3.000

4.  Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.

Authors:  M D Lowe; E Rowland; M J Brown; A A Grace
Journal:  Heart       Date:  2001-07       Impact factor: 5.994

5.  Selective beta1-adrenoceptor blockade enhances the activity of the stimulatory G-protein in human atrial myocardium.

Authors:  T Wang; C Plumpton; M J Brown
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

6.  Beta 2-adrenoceptor-mediated intrinsic sympathomimetic activity of carteolol: an in vivo study.

Authors:  Heike Bruck; Ulrike Poller; Hendrik Lüssenhop; Klaus Pönicke; Thomas Temme; Gerd Heusch; Thomas Philipp; Otto-Erich Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-10-23       Impact factor: 3.000

7.  Beta 1- and beta 2-adrenoceptor-mediated relaxation in human internal mammary artery and saphenous vein: unchanged beta- and alpha-adrenoceptor responsiveness after chronic beta 1-adrenoceptor blockade.

Authors:  A Ferro; A J Kaumann; M J Brown
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

8.  Myocardial ischaemia and ventricular arrhthymias precipitated by physiological concentrations of adrenaline in patients with coronary artery disease.

Authors:  J A Hall; A Ferro
Journal:  Br Heart J       Date:  1992-05

9.  Beta adrenoreceptor subtype cross regulation in the human heart.

Authors:  J A Hall; A Ferro; J E Dickerson; M J Brown
Journal:  Br Heart J       Date:  1993-04

10.  Both beta 1- and beta 2-adrenoceptors mediate catecholamine-evoked arrhythmias in isolated human right atrium.

Authors:  A J Kaumann; L Sanders
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-11       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.